NASDAQ : DBVT
DBV Technologies S.A. — Key statistics
Healthcare · Biotechnology · France
Last price 9.49 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 561.70M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 564.67M |
| Enterprise Value | 409.12M |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 28, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 314.39M |
| Shares Change (YoY) | +213.71% |
| Shares Change (QoQ) | +6.27% |
| Owned by Insiders (%) | 0.03% |
| Owned by Institutions (%) | 50.42% |
| Float | 159.48M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 158.54 |
| Forward PS | 22.05 |
| PB Ratio | 4.01 |
| P/TBV Ratio | 4.01 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 117.19 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.24 |
| Quick Ratio | 2.83 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -406.79 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -205.79% |
| Return on Assets (ROA) | -79.89% |
| Return on Invested Capital (ROIC) | -120.17% |
| Return on Capital Employed (ROCE) | -132.75% |
| Weighted Average Cost of Capital (WACC) | 2.97% |
| Revenue Per Employee | $22,129 |
| Profits Per Employee | -$1.22M |
| Employee Count | 170 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 1.09M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.24 |
| 52-Week Price Change | -37.98% |
| 50-Day Moving Average | 11.42 |
| 200-Day Moving Average | 16.90 |
| Relative Strength Index (RSI) | 36.06 |
| Average Volume (20 Days) | 448,345 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 872,075 |
| Short Previous Month | 1.12M |
| Short % of Shares Out | 1.39% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.42 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 3.76M |
| Gross Profit | 3.76M |
| Operating Income | -208.28M |
| Pretax Income | -206.19M |
| Net Income | -207.28M |
| EBITDA | -205.48M |
| EBIT | -208.28M |
| Loss Per Share | -$2.69 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 165.70M |
| Total Debt | 7.50M |
| Net Cash | 158.20M |
| Net Cash Per Share | $0.50 |
| Equity (Book Value) | 148.60M |
| Book Value Per Share | 0.47 |
| Working Capital | 131.10M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -188.35M |
| Capital Expenditures | -3.42M |
| Depreciation & Amortization | 2.80M |
| Net Borrowing | n/a |
| Free Cash Flow | -191.76M |
| FCF Per Share | -$0.61 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -5,536.36% |
| Pretax Margin | -5,480.91% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -213.71% |
| Shareholder Yield | -213.71% |
| Earnings Yield | -29.94% |
| FCF Yield | -32.15% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $37.16 |
| Price Target Difference | 313.58% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 255.45% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Nov 29, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:5 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |